Bloomberg had an interesting write-up on ebikes, for anyone whose interested. Here's a blurb from it.
@The vibe is buoyant at the headquarters of BH Bikes in Vitoria, a city in Spain’s Basque region. Founded in 1909 as an arms manufacturer, the company switched to bikes after World War I and introduced its first electric model in 2008. Today there are more than 60, ranging in price from about $1,300 to $5,200. “Growth has been tremendous,” says Mikel Quintana, head of the e-bike division, who expects to sell 20,000 this year, up 20 percent from 2015. Across the Atlantic, Don DiCostanzo, the co-founder and chief executive officer of Pedego Electric Bikes, is also pumped. He anticipates his 30-employee company, based in Fountain Valley, Calif., will sell 10,000 of the brightly colored two-wheelers, which start at about $2,300, this year. “What’s critical is we built a distribution system with branded stores, just like Apple,” he says, referring to the company’s network of 83 Pedego dealerships.
I've had enough of your baseless insults. Into Ignore World you go.
What do you have against e-bikes? Even though I personally prefer to ride a non-powered bicycle, I think it's a great alternative mode of transportation, and ~30M Chinese apparently agree. I think TSLA would gain great brand recognition and quickly dominate the space in USA if they decided to make a push into it. Disclaimer: I have no position in TSLA.
I am well versed in world politics and read many reputable world news sources on a regular basis. Unlike you, who apparently takes whatever any blogger chooses to write about as the gospel truth. Grow up.
You have no idea what I believe in. Regardless, you're no screenwriter. And that my dear is a fact.
I appreciate a good movie script. Yours quite frankly sukked rocks so bad I felt obliged to point it out.
And yet you think those six undersigned people who support that post somehow know what that opinion of the public really is huh. You're the one who makes no sense.
You choose to believe what six strangers declared. I choose to trust the views of my six well-educated colleagues on the subject instead. But hey, you just keep calling people you't don't agree with drunks if that makes you feel better.
I don' see what' the mystery is here. As you stated such ETF's are merely vehicles designed to track a target. They are not perfect. Thus they can trade at a premium or discount to the target on any given day.
"We the undersigned"
Why would you think that the opinion of the six undersigned authors of that post is any more reflective of the general view of American Russians than that of six other Russian people you know?
Really? Maybe you should try asking them what they think about terrorism. I'm sure they have an opinion about it.
I know a few Russians and none of them has ever expressed views that even remotely resemble this.
Analyst takes on the new SHPG.
@Jefferies analysts believe the combined company might deliver higher cost savings than planned, based on their discussions with sources close to the company. They also said Shire could strike additional, smaller deals and conduct share repurchases, alongside driving down debt accumulated through the Baxalta tie-up. The deal will also make Shire large enough to drive away potential takeover offers from larger companies, preventing a future AbbVie-type situation.
Credit Suisse analysts commented on the merger in a research note earlier this week, saying, “We publish our updated Shire Baxalta model ahead of the expected deal closing on June 3. We see 5% earnings per share accretion over our stand-alone Shire numbers by 2020. This assumes $500m of operational cost savings, $400m of incremental sales (adding $170m of operating earnings) and a combined group tax rate of 16.5% by 2020."
Duetsche Bank analysts dispelled many of the competitive concerns threatening Baxalta’s hemophilia business in a research note. “We believe investor focus on the threats to Baxalta’s haemophilia franchise mean that the transformational nature of the acquisition has been largely ignored. While we are cognisant of risks on the horizon from potentially paradigm-changing therapies, we believe worst-case investor fears over threats to this franchise are misplaced. Importantly, we see upside to the shares even in bear cases where Baxalta’s franchise sees considerable declines. With our base case forecasts suggesting Shire can deliver a 2016-20 earnings per share compound annual growth rate of more than 15% in return for just 13 times 2017 estimated PE, we reinstate our rating at Buy.”
Strange. It seems that increasingly, knee-jerk reactions like today, are becoming the norm. As if one economic data point and its implications to the likelihood of the Fed raising rates are somehow very significant.